Dong Geng

TL;DR: The CARITUDE-1 trial as discussed by the authors evaluated the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies.

TL;DR: CARTITUDE-1 (NCT03548207) is a chimeric antigen receptor T (CAR-T) cell therapy containing 2 BCMA-targeting single-domain antibodies that presents a newwindow of opportunity for CAR-T cell therapy in patients with central giant cell granuloma.

TL;DR: Cilta-cel is a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies designed to confer avidity in patients with relapsed/refractory multiple myeloma in the US.

TL;DR: Clinical responses appear independent of BM BCMA expression, and the CD4:CD8 ratio and the proportion of T cell memory subsets in the final DP did not correlate with peak CAR+ T cell expansion.

TL;DR: CRS after cilta-cel treatment was low grade and manageable in most patients with R/R MM, and maximum toxicity grade according to the ASTCT consensus grading system could not be derived for 1 patient with CRS in the phase 1b portion.